Reactive Oxygen Species-Induced TXNIP Drives Fructose-Mediated Hepatic Inflammation and Lipid Accumulation Through NLRP3 Inflammasome Activation

Antioxidants and Redox Signaling

Volumn 22, Issue 10, 2015, Pages 848-870

  Zhang, Xian ^a   Zhang, Jian Hua ^a   Chen, Xu Yang ^a   Hu, Qing Hua ^a   Wang, Ming Xing ^a   Jin, Rui ^b   Zhang, Qing Yu ^a   Wang, Wei ^a   Wang, Rong ^a   Kang, Lin Lin ^a   Li, Jin Sheng ^a   Li, Meng ^a   Pan, Ying ^a   Huang, Jun Jian ^b   Kong, Ling Dong ^a  

^a NANJING UNIVERSITY   (China)

^b BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE; ALLOPURINOL; CATALASE; CD163 ANTIGEN; CRYOPYRIN; CYTOKERATIN 18; FRUCTOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; JANUS KINASE 2; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; QUERCETIN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; STAT3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SUPEROXIDE DISMUTASE; SUPPRESSOR OF CYTOKINE SIGNALING 3; THIOREDOXIN INTERACTING PROTEIN; ANTIOXIDANT; CARRIER PROTEIN; CYTOKINE; ENZYME INHIBITOR; NOD-LIKE RECEPTOR 3, RAT; TXNIP PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FOOD INTAKE; FRUCTOSE METABOLISM; GENE SILENCING; HEPATIC PARENCHYMAL CELL; HEPATITIS; HEPG2 CELL LINE; IMMUNOHISTOCHEMISTRY; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIVER CELL; LIVER METABOLISM; LIVER PARENCHYMA; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WEIGHT GAIN; ANIMAL; CELL LINE; DRUG EFFECTS; INFLAMMATION; LIVER; METABOLISM; SECRETION (PROCESS); SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ALLOPURINOL; ANIMALS; ANTIOXIDANTS; CARRIER PROTEINS; CELL LINE; CYTOKINES; ENZYME INHIBITORS; FRUCTOSE; HEPATOCYTES; INFLAMMASOMES; INFLAMMATION; LIPID METABOLISM; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; QUERCETIN; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES;

EID: 84924978525     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.5868     Document Type: Article

References (64)

1. Bakker PJ, Butter LM, Kors L, Teske GJ, Aten J, Sutterwala FS, Florquin S, and Leemans JC. Nlrp3 is a key modulator of diet-induced nephropathy and renal cholesterol accumulation. Kidney Int 85: 1112-1122, 2014.
2. Bischoff SC. Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care 11: 733-740, 2008.
3. Cooper SR, Taylor JK, Miraglia LJ, and Dean NM. Pharmacology of antisense oligonucleotide inhibitors of protein expression. Pharmacol Ther 82: 427-435, 1999.
4. Crooke ST. Basic principles of antisense therapeutics. In: Antisense Research and Application. edited by Crooke ST. Berlin: Springer, 1998, pp. 1-50.
5. Demirel U, Yalniz M, Aygun C, Orhan C, Tuzcu M, Sahin K, Ozercan IH, and Bahcecioglu IH. Allopurinol ameliorates thioacetamide-induced acute liver failure by regulating cellular redox-sensitive transcription factors in rats. Inflammation 35: 1549-1557, 2012.
6. Deng XQ, Chen LL, and Li NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int 27: 708-715, 2007.
7. Esser N, L'Homme L, De Roover A, Kohnen L, Scheen AJ, Moutschen M, Piette J, Legrand-Poels S, and Paquot N. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 56: 2487-2497, 2013.
8. Frenzel J, Richter J, and Eschrich K. Fructose inhibits apoptosis induced by reoxygenation in rat hepatocytes by decreasing reactive oxygen species via stabilization of the glutathione pool. Biochim Biophys Acta 1542: 82-94, 2002.
9. Gasse P, Riteau N, Charron S, Girre S, Fick L, Petrilli V, Tschopp J, Lagente V, Quesniaux VF, Ryffel B, and Couillin I. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 179: 903-913, 2009.
10. Griffith JW, Sun T, McIntosh MT, and Bucala R. Pure Hemozoin is inflammatory in vivo and activates the NALP3 inflammasome via release of uric acid. J Immunol 183: 5208-5220, 2009.
11. He X and Ma Q. Redox regulation by nuclear factor erythroid 2-related factor 2: gatekeeping for the basal and diabetes-induced expression of thioredoxin-interacting protein. Mol Pharmacol 82: 887-897, 2012.
12. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, and Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482: 179-185, 2012.
13. Hu QH, Wang C, Li JM, Zhang DM, and Kong LD. Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement. Am J Physiol Renal Physiol 297: F1080-F1091, 2009.
14. Hu QH, Zhang X, Pan Y, Li YC, and Kong LD. Allopurinol, quercetin and rutin ameliorate renal NLRP3 inflammasome activation and lipid accumulation in fructose-fed rats. Biochem Pharmacol 84: 113-125, 2012.
15. Huang H, Chen HW, Evankovich J, Yan W, Rosborough BR, Nace GW, Ding Q, Loughran P, Beer-Stolz D, Billiar TR, Esmon CT, and Tsung A. Histones activate the NLRP3 inflammasome in Kupffer cells during sterile inflammatory liver injury. J Immunol 191: 2665-2679, 2013.
16. Karim S, Adams DH, and Lalor PF. Hepatic expression and cellular distribution of the glucose transporter family. World J Gastroenterol 18: 6771-6781, 2012.
17. Kim GN and Jang HD. Protective mechanism of quercetin and rutin using glutathione metabolism on HO-induced oxidative stress in HepG2 cells. Ann N Y Acad Sci 1171: 530-537, 2009.
18. Kim HY, Kim SJ, and Lee SM. Activation of NLRP3 and AIM2 inflammasomes in Kupffer cells in hepatic ischemia/ reperfusion. FEBS J 282: 259-270, 2015.
19. Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol 11: 213-220, 2011.
20. Le KA and Tappy L. Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care 9: 469-475, 2006.
21. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, and Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 62: 194-204, 2013.
22. Li JM, Li YC, Kong LD, and Hu QH. Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats. Hepatology 51: 1555-1566, 2010.
23. Li Y, Xu S, Jiang B, Cohen RA, and Zang M. Activation of sterol regulatory element binding protein and NLRP3 inflammasome in atherosclerotic lesion development in diabetic pigs. PLoS One 8: e67532, 2013.
24. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, and Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 7: 251-264, 2010.
25. Lotowska JM, Sobaniec-Lotowska ME, and Lebensztejn DM. The role of Kupffer cells in the morphogenesis of nonalcoholic steatohepatitis - ultrastructural findings. The first report in pediatric patients. Scand J Gastroenterol 48: 352-357, 2013.
26. Lu J and Holmgren A. The thioredoxin antioxidant system. Free Radic Biol Med 66: 75-87, 2014.
27. Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53: 401-426, 2013.
28. Marcolin E, San-Miguel B, Vallejo D, Tieppo J, Marroni N, Gonzalez-Gallego J, and Tunon MJ. Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. J Nutr 142: 1821-1828, 2012.
29. Milovanova T, Manevich Y, Haddad A, Chatterjee S, Moore JS, and Fisher AB. Endothelial cell proliferation associated with abrupt reduction in shear stress is dependent on reactive oxygen species. Antioxid Redox Signal 6: 245-258, 2004.
30. Miura K, Yang L, van Rooijen N, Brenner DA, Ohnishi H, and Seki E. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 57: 577-589, 2013.
31. Moschen AR, Molnar C, Enrich B, Geiger S, Ebenbichler CF, and Tilg H. Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med 17: 840-845, 2011.
32. Mouralidarane A, Soeda J, Visconti-Pugmire C, Samuelsson AM, Pombo J, Maragkoudaki X, Butt A, Saraswati R, Novelli M, Fusai G, Poston L, Taylor PD, and Oben JA. Maternal obesity programs offspring nonalcoholic fatty liver disease by innate immune dysfunction in mice. Hepatology 58: 128-138, 2013.
33. Nagai Y, Yonemitsu S, Erion DM, Iwasaki T, Stark R, Weismann D, Dong J, Zhang D, Jurczak MJ, Loffler MG, Cresswell J, Yu XX, Murray SF, Bhanot S, Monia BP, Bogan JS, Samuel V, and Shulman GI. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab 9: 252-264, 2009.
34. Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, Delker DA, Jo J, Bertoletti A, Hagedorn CH, and Gale M, Jr. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 9: e1003330, 2013.
35. Nivet-Antoine V, Cottart CH, Lemarechal H, Vamy M, Margaill I, Beaudeux JL, Bonnefont-Rousselot D, and Borderie D. Trans-Resveratrol downregulates Txnip overexpression occurring during liver ischemia-reperfusion. Biochimie 92: 1766-1771, 2010.
36. Nomura K and Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 23: 203-208, 2012.
37. Oka S, Liu W, Yoshihara E, Ahsan MK, Ramos DA, Son A, Okuyama H, Zhang L, Masutani H, Nakamura H, and Yodoi J. Thioredoxin binding protein-2 mediates metabolic adaptation in response to lipopolysaccharide in vivo. Crit Care Med 38: 2345-2351, 2010.
38. Panchal SK, Poudyal H, and Brown L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J Nutr 142: 1026-1032, 2012.
39. Park MJ, Kim DI, Lim SK, Choi JH, Kim JC, Yoon KC, Lee JB, Lee JH, Han HJ, Choi IP, Kim HC, and Park SH. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1alpha regulation in vitro and in vivo. J Hepatol 61: 1151-1157, 2014.
40. Peglow S, Toledo AH, Anaya-Prado R, Lopez-Neblina F, Toledo-Pereyra LH. Allopurinol and xanthine oxidase inhibition in liver ischemia reperfusion. J Hepatobiliary Pancreat Sci 18: 137-146, 2011.
41. Pejznochova M, Tesarova M, Hansikova H, Magner M, Honzik T, Vinsova K, Hajkova Z, Havlickova V, and Zeman J. Mitochondrial DNA content and expression of genes involved in mtDNA transcription, regulation and maintenance during human fetal development. Mitochondrion 10: 321-329, 2010.
42. Ramyaa P, Krishnaswamy R, and Padma VV. Quercetin modulates OTA-induced oxidative stress and redox signalling in HepG2 cells - up regulation of Nrf2 expression and down regulation of NF-kappaB and COX-2. Biochim Biophys Acta 1840: 681-692, 2014.
43. Reiniers MJ, van Golen RF, van Gulik TM, and Heger M. Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver. Antioxid Redox Signal 21: 1119-1142, 2014.
44. Russo M, Spagnuolo C, Tedesco I, Bilotto S, and Russo GL. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol 83: 6-15, 2012.
45. Smith BW and Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 48: 97-113, 2011.
46. Spruss A and Bergheim I. Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J Nutr Biochem 20: 657-662, 2009.
47. Spruss A, Kanuri G, Stahl C, Bischoff SC, and Bergheim I. Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest 92: 1020-1032, 2012.
48. Spruss A, Kanuri G, Uebel K, Bischoff SC, and Bergheim I. Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice. Antioxid Redox Signal 14: 2121-2135, 2011.
49. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, and Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 50: 1094-1104, 2009.
50. Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D, Neale GA, Hooiveld GJ, Hijmans A, Vroegrijk I, van den Berg S, Romijn J, Rensen PC, Joosten LA, Netea MG, and Kanneganti TD. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A 108: 15324-15329, 2011.
51. Suzuki I, Yamauchi T, Onuma M, and Nozaki S. Allopurinol, an inhibitor of uric acid synthesis - can it be used for the treatment of metabolic syndrome and related disorders? Drugs Today (Barc) 45: 363-378, 2009.
52. Takahashi Y, Kobayashi Y, Kawata K, Kawamura K, Sumiyoshi S, Noritake H, Watanabe S, Chida T, Souda K, Sakaguchi T, Nakamura H, and Suda T. Does hepatic oxidative stress enhance activation of nuclear factor-E2-related factor in patients with nonalcoholic steatohepatitis? Antioxid Redox Signal 20: 538-543, 2014.
53. Thannickal VJ and Fanburg BL. Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1. J Biol Chem 270: 30334-30338, 1995.
54. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 28: 179-185, 2010.
55. Tschopp J and Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10: 210-215, 2010.
56. Ulman EA, Ifft KH, Kari FW, and Visek WJ. Fatty liver of growing rats fed excess lysine and its prevention by adenine or allopurinol. Lipids 16: 393-396, 1981.
57. Valeri F, Boess F, Wolf A, Goldlin C, and Boelsterli UA. Fructose and tagatose protect against oxidative cell injury by iron chelation. Free Radic Biol Med 22: 257-268, 1997.
58. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, and Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17: 179-188, 2011.
59. Vos MB and Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 57: 2525-2531, 2013.
60. Zhang HF, Shi LJ, Song GY, Cai ZG, Wang C, and An RJ. Protective effects of matrine against progression of high-fructose diet-induced steatohepatitis by enhancing antioxidant and anti-inflammatory defences involving Nrf2 translocation. Food Chem Toxicol 55: 70-77, 2013.
61. Zhao C, Gillette DD, Li X, Zhang Z, and Wen H. Nuclear factor E2-related factor-2 (Nrf2) is required for NLRP3 and AIM2 inflammasome activation. J Biol Chem 289: 17020-17029, 2014.
62. Zhou R, Tardivel A, Thorens B, Choi I, and Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11: 136-140, 2010.
63. Zhou R, Yazdi AS, Menu P, and Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469: 221-225, 2011.
64. Zou X, Yan C, Shi Y, Cao K, Xu J, Wang X, Chen C, Luo C, Li Y, Gao J, Pang W, Zhao J, Zhao F, Li H, Zheng A, Sun W, Long J, Szeto IM, Zhao Y, Dong Z, Zhang P, Wang J, Lu W, Zhang Y, Liu J, and Feng Z. Mitochondrial dysfunction in obesity-associated nonalcoholic fatty liver disease: the protective effects of pomegranate with its active component punicalagin. Antioxid Redox Signal 21: 1557-1570, 2014.